KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Receivables: 2020-2024

Historic Change in Receivables for Esperion Therapeutics (ESPR) over the last 5 years, with Dec 2024 value amounting to $31.6 million.

  • Esperion Therapeutics' Change in Receivables rose 50.51% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year increase of 102.99%. This contributed to the annual value of $31.6 million for FY2024, which is 114.34% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Change in Receivables of $31.6 million as of FY2024, which was up 114.34% from $14.8 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Change in Receivables registered a high of $31.6 million during FY2024, and its lowest value of $10.5 million during FY2021.
  • Its 3-year average for Change in Receivables is $19.1 million, with a median of $14.8 million in 2023.
  • Its Change in Receivables has fluctuated over the past 5 years, first dropped by 14.87% in 2021, then skyrocketed by 114.34% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Change in Receivables (Yearly) stood at $12.4 million in 2020, then declined by 14.87% to $10.5 million in 2021, then grew by 2.36% to $10.8 million in 2022, then skyrocketed by 36.78% to $14.8 million in 2023, then soared by 114.34% to $31.6 million in 2024.